• Announcement
  • Miscellaneous

Job Offer – Microfluidics Automation Lead

Job tittle 

Microfluidics Automation Lead

Job description

OKOMERA is seeking an exceptional profile to lead its microfluidic automation development. Automation is one of OKOMERA’s main feature, since it enables non experts to robustly use our microfluidic chips. After a first prototype, Okomera is developing an alpha instrument that will be installed at the client’s site by the end of 2021.The main missions of the automation lead will be: 1) to lead the design and optimization of OKOMERA’s fluidic machines (present and future), complying with proper regulatory norm, 2) toparticipate in technical customer support and to collect their feedback, 3) to hire and manage a team of microfluidic engineers. The candidate will work closely with the CTO. Details of missions will vary depending on the level ofexpertise of the recruited profile.


  • Education : Master of Science or Engineer degree (or higher)
  • 3+ years of industrial experience in laboratory instrumentation
  • Strong industrial design and project management skills
  • Great experimental and practical skills, innovative problem solving
  • Good programming skills (Python, C++… )
  • Good understanding of fluid mechanics at the microscale
  • Great organization and management skills proven by experience
  • Ability to work in English within an international team

Ideal candidates may have

  • Previous experience in 3D cell culture or high throughput drug screening
  • Experience in CE-IVD instrumentation

Contract : CDI

Starting Date : from February 2022

Salary : based on experience

Education Level : Master of Science, Engineering degree or PhD, 3+ years of industrial experience

Location : Paris, Brain Institute (ICM), Hôpital Pitié-Salpêtrière


About Okomera and Microfluidics for clinical oncology

OKOMERA is a newly created start-up (2020) spun out from Ecole Polytechnique and Institut Pasteur, whose key mission is to help selecting the best treatment for each cancer patient. OKOMERA is currently codeveloping functional ex vivo assays with our clients, key opinion leaders leading research inprecision cancer medicine.

OKOMERA clients currently use our 3D cell culture microfluidic technology [1] to cultivate primary patient cells from tumor biopsies, and/or cell lines, to assess cell functionalities(drug sensitivity, morphology, migration). OKOMERA’s droplet array technology enables to automate the formation of complex 3D cell cultures (micro-tumors with co-cultures, hydrogels), and to test tens to hundreds of individual conditions on a single chip [2]. OKOMERA prides itself on supplying easy-to-use products (fluidic machine, chips and software) built for non-experts who wish to automate high-throughput 3D sample testing.

OKOMERA was awarded the national iLAB prize from BPI France in 2019, the COMET program from WILCO, iscurrently incubated at Hôpital Pitié Salpêtrière in Paris and recently finalized its initial funding round. We are currently a team of 7, and are actively hiring to grow and deliver our alpha solution to our first clients in early 2022.

Contact info

Raphaël TOMASI – Cofounder & CTO – communications@okomera.com


1- Sart, R. F.-X. Tomasi, G. Amselem, and C. N. Baroud, “Multiscale cytometry and regulation of 3D cellcultures on a chip,” Nat. Commun., vol. 8, p. 469, 2017.
2- F. X. Tomasi, S. Sart, T. Champetier, and C. N. Baroud, “Individual Control and Quantification of 3DSpheroids in a High-Density Microfluidic Droplet Array,” Cell Rep., vol. 31, no. 8, 2020.